The proposed sale is small in absolute terms and likely part of routine equity monetization by an officer. Monitor for actual Form 4 filings to confirm execution; no immediate read-through for company fundamentals.
Price Chart
Executive Summary
Dirk Thye, an officer of IRulya Therapeutics Inc., filed a Form 144 on October 21, 2026, indicating intent to sell 3,700 shares of common stock with an estimated aggregate market value of $133,328.85. The shares were acquired via RSU vesting on October 30, 2025, and the sale is planned through Merrill Lynch. This is a relatively small proposed sale relative to typical insider holdings, but the filing signals insider intent to monetize equity ahead of any potential catalyst.
Key Facts
- Insider Dirk Thye (Officer) filed Form 144 to sell 3,700 shares of common stock.
- Estimated aggregate market value of proposed sale: $133,328.85.
- Shares acquired via RSU vesting on October 30, 2025.
- Broker for the sale: Merrill Lynch, 555 California St, San Francisco, CA.
- Form 144 filed on October 21, 2026; sale intended to occur on or after that date.
- Company has undergone name changes from Quince Therapeutics, Inc. (2022) and Cortexyme, Inc. (2016).
Financial Impact
Proposed sale of 3,700 shares valued at ~$133k, representing a modest portion of the insider's likely holdings.
Risk Factors
- Insider sale could signal reduced conviction if followed by larger or more frequent filings.
- Form 144 is an intent notice; sale may not occur, but filing itself indicates insider considered selling.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-066751 |
| Document: 0001628280-26-066751-index.html | 0001628280-26-066751 |
| Document: 0001628280-26-066751.txt | 0001628280-26-066751 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 144 | $32.83 | awaiting T+20 | — | $32.47 (−1.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 8-K | $34.45 | awaiting T+20 | — | $32.47 (−5.73%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.47 (−2.27%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.47 (−2.27%) |
Oct 6, 2026 21d ago | 8-K | $26.72 | awaiting T+20 | — | $32.47 (+21.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers